No Data
No Data
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing.The Maryland-based company'
Positive Outlook on Elevation Oncology: Anticipating EO-3021 Data Release Impact
Piper Sandler Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $10
Piper Sandler analyst Biren Amin maintains $Elevation Oncology(ELEV.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 42.2% an
Express News | JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
TD Cowen Maintains Elevation Oncology(ELEV.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Elevation Oncology(ELEV.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.1% and a total average return of 16.0% over the p
JMP Securities Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $7
JMP Securities analyst Silvan Tuerkcan maintains $Elevation Oncology(ELEV.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 34.
No Data